Most-Favored Nation Drug Pricing: An Update

IPD Analytics has released a new report that analyzes the recent developments in the Trump administration’s most-favored-nation (MFN) drug pricing initiative. Introduced through an executive order in May 2025, the MFN policy has advanced rapidly. As of January 2026, AbbVie became the 16th manufacturer to confirm an MFN agreement with the administration, while Regeneron has indicated that its agreement is imminent.

The report also reviews the Center for Medicare & Medicaid Services’ (CMS’) introduction of three innovation models, GENEROUS, GLOBE, and GUARD, to support the implementation of MFN pricing across Medicaid and Medicare. While the models share some similarities, they differ in methodology for determining the MFN price, and key elements of the GLOBE and GUARD Models are not yet final. At this time, MFN agreements and CMS models do not directly impact the commercial payer market, though further clarification is anticipated as implementation details continue to evolve.